Il-4 prevents the blockade of dendritic cell differentiation induced by tumor cells

Cancer Research

Volumn 61, Issue 7, 2001, Pages 3096-3104

  Menetrier Caux, Christine ^a   Thomachot, Marie Cécile ^a   Alberti, Laurent ^a   Montmain, Gilles ^a   Blay, Jean Yves ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; GLYCOPROTEIN GP 130; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6;

ALPHA CHAIN; ANTIGEN PRESENTING CELL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MINIMUM INHIBITORY CONCENTRATION; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

ANTIGENS, CD; ANTIGENS, CD34; CARCINOMA, RENAL CELL; CELL DIFFERENTIATION; CULTURE MEDIA; CYTOKINE RECEPTOR GP130; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMANS; INTERLEUKIN-13; INTERLEUKIN-4; KIDNEY NEOPLASMS; MEMBRANE GLYCOPROTEINS; MONOCYTES; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; RECEPTORS, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; STEM CELLS;

EID: 0035300580     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. The dendritic cell system and its role in immunogenicity
2. Antigen presenting cell types
3. Myeloid dendritic cells
4. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
5. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
6. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
7. CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer
8. Infusion of dendritic cells pulsed with HLAA2-specific prostate-specific membrane antigen peptides: A Phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease
9. Dendritic cell immuno-therapy in disseminated parathyroid carcinoma
10. Human renal-cell carcinoma tissue contains dendritic cells
11. Minimal recruitment and activation of dendritic cells within renal cell carcinoma
12. Prospective randomized trial of interferon α-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer
13. Recombinant human interleukin-2, recombinant human interferon α-2a, or both in metastatic renal-cell carcinoma
14. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes, I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines
15. Cellular immune response to human renal-cell carcinomas: Definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocyte (CTL) clones
16. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma
17. Tumor antigens recognized by T cells
18. A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription
19. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma
20. Interleukin-6 and TNF α production in human renal cell carcinoma
21. Comparison of cytogenetics, cytokine secretion, and oncogene expression in primary cultures of renal carcinoma cells
22. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: Role of interleukin-6 and macrophage colony-stimulating factor
23. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
24. Downregulation of interleukin-12 (IL-12) responsiveness in human T cells by transforming growth factor-β: Relationship with IL- 12 signaling
25. The host-tumor immune conflict: From immunosuppression to resistance and destruction
26. Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor
27. Interleukin-6 synergizes with M-CSF in the formation of macrophage colonies from purified human marrow progenitor cells
28. Inhibition of human macrophage colony formation by interleukin 4
29. The influence of interleukin (IL)-4, IL-13, and Flt3 ligand on human dendritic cell differentiation from cord blood CD34+ progenitor cells
30. IL-4 addition during differentiation of CD34 progenitors delays maturation of dendritic cells while promoting their survival
31. Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma
32. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α
33. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF α
34. Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-colony-forming unit intermediate
35. + hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GMCSF+TNFα
36. Respective involvement of TGF-β and IL-4 in the development of Langerhans cells and non-Langerhans dendritic cells from CD34+ progenitors
37. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells
38. IL-4 and IL-13 specifically increase adhesion molecule and inflammatory cytokine expression in human lung fibroblasts
39. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability
40. Interleukin-4 and interleukin-13: Their similarities and discrepancies
41. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6
42. Dendritic cells: From ontogenetic orphans to myelomonocytic descendants
43. Molecular cloning and expression of an IL-6 signal transducer, gp130
44. Molecular cloning of a murine IL-6 receptor-associated signal transducer, gp130, and its regulated expression in vivo
45. Critical role of IL-12 in dendritic cell-induced differentiation of naive B lymphocytes
46. Proliferating dendritic cell progenitors in human blood
47. Differentiation of human dendritic cells from monocytes in vitro
48. Synergistic effects of IL-4 and either GM-CSF or IL-3 on the induction of CD23 expression by human monocytes: Regulatory effects of IFN-α and IFN-γ
49. Generation of human dendritic cells/Langerhans cells from circulating CD34+ hematopoietic progenitor cells
50. Expression of the nlsLacz gene in dendritic cells derived from retrovirally transduced peripheral blood CD34+ cells
51. Generation of dendritic cells from bone marrow progenitors using GM-CSF. TNF-α, and additional cytokines: Antagonistic effects of IL-4 and IFN-γ and selective involvement of TNF-α receptor-1
52. IL-4 and CD40 ligation affect differently the differentiation, maturation, and function of human CD34+ cell-derived CD1a+
53. Type I IFNs enhance the terminal differentiation of dendritic cells
54. Human dendritic cell differentiation pathway from CD34+ hematopoietic precursor cells
55. Interleukin-13 is involved in functional maturation of human peripheral blood monocyte-derived dendritic cells
56. Macrophage-colony-stimulating factor expression by anti-CD45 stimulated human monocytes is transcriptionally up-regulated by IL-1 β and inhibited by IL-4 and IL-10
57. Development of accessory phenotype and function during the differentiation of monocyte-derived dendritic cells
58. Human recombinant interleukin 4 induces Fc ε receptors (CD23) on normal human B lymphocytes
59. Human recombinant interleukin 4 induces normal B cells to produce soluble CD23/IgE-binding factor analogous to that spontaneously released by lymphoblastoid B cell lines
60. Human recombinant interleukin 4 induces Fc ε R2/CD23 on normal human monocytes
61. Induction of the low affinity receptor for IgE (Fc ε RII/CD23) on human blood dendritic cells by interleukin-4
62. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells
63. Interleukin-13 selectively suppresses the growth of human macrophage progenitors at the late stage
64. Interactions of tumor necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow
65. Generation of dendritic cells from peripheral blood adherent cells in medium with human serum
66. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: Implications for live kidney cancer vaccines
67. Serum levels of cytokines in patients with colorectal cancer: Possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis
68. Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: A French multiinstitutional study